NervGen Pharma(DE:9UA)
€1.20+0.05 (+4.35%)
DE:9UA
NervGen Pharma stock drug pipeline
€1.20
At close:+0.05 (+4.35%)
NervGen Pharma (9UA) Drug Pipeline
3 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nervgen Pharma Corp (DE:9UA) have in its pipeline
NervGen Pharma DE:9UA is currently developing the following drugs: Nvg-291. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

